Dermata Therapeutics Q3 2022: cash $8.1M; DMT310 rosacea Phase 2 top-line due Dec 2022

Dermata Therapeutics, Inc.

Cash and equivalents $8.1M as of Sep 30, 2022, down from $10.8M at Dec 31, 2021; runway into Q3 2023.
R&D expenses $1.6M (Q3 2022) vs $0.8M (Q3 2021) due to increased DMT310 program costs.
G&A expenses flat at $0.9M; stock-based comp $0.2M for G&A and $0.05M for R&D in Q3 2022.
DMT310 Phase 2 topline results in moderate-to-severe rosacea expected December 2022.
DMT310 Phase 3 program for moderate-to-severe acne anticipated to start 1H 2023 after FDA meeting.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.4

Dermata Therapeutics, Inc. reported financial results for quarter ended September 30, 2022.

Period: quarter ended September 30, 2022
Result: reported results

Exact text from the filing

Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal period ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Dermata Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-22-015036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.